BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Boyer-diaz Z, Aristu-zabalza P, Andrés-rozas M, Robert C, Ortega-ribera M, Fernández-iglesias A, Broqua P, Junien J, Wettstein G, Bosch J, Gracia-sancho J. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease. Journal of Hepatology 2021;74:1188-99. [DOI: 10.1016/j.jhep.2020.11.045] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Mitten EK, Baffy G. Mechanotransduction in the pathogenesis of nonalcoholic fatty liver disease. J Hepatol 2022:S0168-8278(22)03059-8. [PMID: 36063966 DOI: 10.1016/j.jhep.2022.08.028] [Reference Citation Analysis]
2 Teng T, Qiu S, Zhao Y, Zhao S, Sun D, Hou L, Li Y, Zhou K, Yu X, Yang C, Li Y. Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2022;23:7841. [PMID: 35887189 DOI: 10.3390/ijms23147841] [Reference Citation Analysis]
3 Guixé-Muntet S, Biquard L, Szabo G, Dufour JF, Tacke F, Francque S, Rautou PE, Gracia-Sancho J. Review article: vascular effects of PPARs in the context of NASH. Aliment Pharmacol Ther 2022;56:209-23. [PMID: 35661191 DOI: 10.1111/apt.17046] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Rodrigues SG, Mendoza YP, Bosch J. Investigational drugs in early clinical development for portal hypertension. Expert Opin Investig Drugs 2022. [PMID: 35758843 DOI: 10.1080/13543784.2022.2095259] [Reference Citation Analysis]
5 Shan L, Wang F, Zhai D, Meng X, Liu J, Lv X. New Drugs for Hepatic Fibrosis. Front Pharmacol 2022;13:874408. [DOI: 10.3389/fphar.2022.874408] [Reference Citation Analysis]
6 Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin 2022;43:1191-9. [PMID: 34907360 DOI: 10.1038/s41401-021-00822-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lange NF, Graf V, Caussy C, Dufour JF. PPAR-Targeted Therapies in the Treatment of Non-Alcoholic Fatty Liver Disease in Diabetic Patients. Int J Mol Sci 2022;23:4305. [PMID: 35457120 DOI: 10.3390/ijms23084305] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
8 Almohawes ZN, El-kott A, Morsy K, Shati AA, El-kenawy AE, Khalifa HS, Elsaid FG, Abd-lateif AM, Abu-zaiton A, Ebealy ER, Abdel-daim MM, Ghanem RA, Abd-ella EM. Salidroside inhibits insulin resistance and hepatic steatosis by downregulating miR-21 and subsequent activation of AMPK and upregulation of PPARα in the liver and muscles of high fat diet-fed rats. Archives of Physiology and Biochemistry. [DOI: 10.1080/13813455.2021.2024578] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
9 Trauner M, Fuchs CD. Novel therapeutic targets for cholestatic and fatty liver disease. Gut 2022;71:194-209. [PMID: 34615727 DOI: 10.1136/gutjnl-2021-324305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
10 Zhang J, Liu Q, He J, Li Y. Novel Therapeutic Targets in Liver Fibrosis. Front Mol Biosci 2021;8:766855. [PMID: 34805276 DOI: 10.3389/fmolb.2021.766855] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Gibert-Ramos A, Sanfeliu-Redondo D, Aristu-Zabalza P, Martínez-Alcocer A, Gracia-Sancho J, Guixé-Muntet S, Fernández-Iglesias A. The Hepatic Sinusoid in Chronic Liver Disease: The Optimal Milieu for Cancer. Cancers (Basel) 2021;13:5719. [PMID: 34830874 DOI: 10.3390/cancers13225719] [Reference Citation Analysis]
12 Qu W, Ma T, Cai J, Zhang X, Zhang P, She Z, Wan F, Li H. Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies. Front Med (Lausanne) 2021;8:761538. [PMID: 34746195 DOI: 10.3389/fmed.2021.761538] [Reference Citation Analysis]
13 Kronborg TM, Ytting H, Hobolth L, Møller S, Kimer N. Novel Anti-inflammatory Treatments in Cirrhosis. A Literature-Based Study. Front Med (Lausanne) 2021;8:718896. [PMID: 34631742 DOI: 10.3389/fmed.2021.718896] [Reference Citation Analysis]
14 Kuchay MS, Martínez-Montoro JI, Choudhary NS, Fernández-García JC, Ramos-Molina B. Non-Alcoholic Fatty Liver Disease in Lean and Non-Obese Individuals: Current and Future Challenges. Biomedicines 2021;9:1346. [PMID: 34680463 DOI: 10.3390/biomedicines9101346] [Reference Citation Analysis]
15 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Reference Citation Analysis]
16 Derrett-Smith E, Clark KEN, Shiwen X, Abraham DJ, Hoyles RK, Lacombe O, Broqua P, Junien JL, Konstantinova I, Ong VH, Denton CP. The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis. Arthritis Res Ther 2021;23:234. [PMID: 34488870 DOI: 10.1186/s13075-021-02592-x] [Reference Citation Analysis]
17 Königshofer P, Brusilovskaya K, Petrenko O, Hofer BS, Schwabl P, Trauner M, Reiberger T. Nuclear Receptors in Liver Fibrosis. Biochim Biophys Acta Mol Basis Dis 2021;:166235. [PMID: 34339839 DOI: 10.1016/j.bbadis.2021.166235] [Reference Citation Analysis]
18 Wang Z, Jiang S, Liu S, Peng J, Hu S, Wang X, Zhuo W, Liu T, Guo J, Zhou H, Yang Z, Mao X, Liu Z. Metabolomics of Artichoke Bud Extract in Spontaneously Hypertensive Rats. ACS Omega 2021;6:18610-22. [DOI: 10.1021/acsomega.1c01135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Han QJ, Mu YL, Zhao HJ, Zhao RR, Guo QJ, Su YH, Zhang J. Fasudil prevents liver fibrosis via activating natural killer cells and suppressing hepatic stellate cells. World J Gastroenterol 2021; 27(24): 3581-3594 [PMID: 34239271 DOI: 10.3748/wjg.v27.i24.3581] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
20 Manicardi N, Fernández-Iglesias A, Abad-Jordà L, Royo F, Azkargorta M, Ortega-Ribera M, Sanfeliu-Redondo D, Martínez-Alcocer A, Elortza F, Hessheimer AJ, Fondevila C, Lozano JJ, García-Pagán JC, Bosch J, Cubero FJ, Albillos A, Vaquero J, Falcón-Pérez JM, Gracia-Sancho J. Transcriptomic Profiling of the Liver Sinusoidal Endothelium during Cirrhosis Reveals Stage-Specific Secretory Signature. Cancers (Basel) 2021;13:2688. [PMID: 34072510 DOI: 10.3390/cancers13112688] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
21 Ma H, Liu X, Zhang M, Niu J. Liver sinusoidal endothelial cells are implicated in multiple fibrotic mechanisms. Mol Biol Rep 2021;48:2803-15. [PMID: 33730288 DOI: 10.1007/s11033-021-06269-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Wang X, Luo X, Yang L. Risk Factors for Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt: Beyond Stent Diameter. Dig Dis Sci 2021. [PMID: 33634428 DOI: 10.1007/s10620-021-06868-9] [Reference Citation Analysis]
23 Gracia-sancho J, Caparrós E, Fernández-iglesias A, Francés R. Role of liver sinusoidal endothelial cells in liver diseases. Nat Rev Gastroenterol Hepatol 2021;18:411-31. [DOI: 10.1038/s41575-020-00411-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 30.0] [Reference Citation Analysis]